Antibody-drug conjugate extends overall survival in cervical cancer
In the Phase III innovaTV 301 trial in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy, Tivdak (tisotumab vedotin-tftv), compared with chemotherapy alone, met its primary endpoint of overall survival (OS). An independent data monitoring committee determined that OS crossed… Read More